TaiDoc Technology (TPE:4736) Cash Conversion Cycle: 213.89 (As of Dec. 2025)


TPE:4736 TaiDoc Technology Corp TPE:4736
73 GF Score
Price NT$126.00
GF Value NT$111.57
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is TaiDoc Technology Cash Conversion Cycle?

TaiDoc Technology TPE:4736 +2.02% 73 Cash Conversion Cycle is 213.89 as of Dec. 2025. GuruFocus rates TPE:4736 with a GF Score™ of 73/100 and a GF Value™ of NT$111.57 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

TaiDoc Technology's Days Sales Outstanding for the three months ended in Dec. 2025 was 81.79.
TaiDoc Technology's Days Inventory for the three months ended in Dec. 2025 was 187.51.
TaiDoc Technology's Days Payable for the three months ended in Dec. 2025 was 55.41.
Therefore, TaiDoc Technology's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2025 was 213.89.


TaiDoc Technology  (TPE:4736) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


TaiDoc Technology Cash Conversion Cycle Related Terms


TaiDoc Technology Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for TaiDoc Technology's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiDoc Technology Cash Conversion Cycle Chart

TaiDoc Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.18 134.52 208.14 188.45 214.77

TaiDoc Technology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 193.75 239.47 246.72 212.33 213.89

TPE:4736 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison

For the Medical Devices subindustry, TaiDoc Technology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiDoc Technology Cash Conversion Cycle vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TaiDoc Technology's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where TaiDoc Technology's Cash Conversion Cycle falls into.


TPE:4736
73GF Score
TaiDoc Technology Corp TPE:4736
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiDoc Technology Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

TaiDoc Technology's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=84.19+199.19-68.61
=214.77

TaiDoc Technology's Cash Conversion Cycle for the quarter that ended in Dec. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=81.79+187.51-55.41
=213.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 213.89 mean?
TaiDoc Technology (TPE:4736) has a Cash Conversion Cycle of 213.89 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on TaiDoc Technology and its competitors.
Is TaiDoc Technology's Cash Conversion Cycle too high?
TaiDoc Technology's current Cash Conversion Cycle is 213.89. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. TaiDoc Technology's value of 213.89 is 36.3% above this industry median. Overall, TaiDoc Technology has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TaiDoc Technology's Cash Conversion Cycle compare to ABT and SYK?
TaiDoc Technology's Cash Conversion Cycle of 213.89 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. TaiDoc Technology's value of 213.89 is 36.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiDoc Technology's current Cash Conversion Cycle of 213.89 is 36.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on TaiDoc Technology and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiDoc Technology's current Cash Conversion Cycle is 213.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiDoc Technology stock overvalued right now?
Based on GuruFocus' analysis, TaiDoc Technology (TPE:4736) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$111.57, compared to a current price of NT$126.00 — trading 12.9% above its estimated fair value. The current Cash Conversion Cycle is 213.89 and 36.3% above the Medical Devices & Instruments industry median of 156.96. TaiDoc Technology's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For TaiDoc Technology (TPE:4736), the current Cash Conversion Cycle is 213.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiDoc Technology (TPE:4736) Overvalued in 2026?

Based on GuruFocus' analysis, TaiDoc Technology stock appears to be overvalued. The current stock price of NT$126.00 is trading 12.9% above its estimated GF Value™ of NT$111.57. GuruFocus considers TaiDoc Technology to be Modestly Overvalued.

Key valuation signals for TPE:4736:

  • Cash Conversion Cycle: 213.89
  • GF Value™: NT$111.57 vs. price of NT$126.00 (12.9% above fair value)
  • GF Score™: 73/100 with 4 warning signs
  • Industry Position: 36.3% above the Medical Devices & Instruments median

No single metric tells the full story. See the TPE:4736 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiDoc Technology Business Description

Address Wugong 2nd Road, 6th Floor, No. 127, Wugu District, New Taipei City, TWN, 24888
TaiDoc Technology Corp is engaged in the research and development, manufacture, and sales of various electronics components and medical devices. Its products and services include In Vitro Diagnostic, Medical Device, and TeleHealth. It has three segments: Manufacturing of Medical Devices, Precision Finishing Division, and Sales of Medical Devices. It derives the majority of its revenue from the Manufacturing of Medical Devices. Geographically, the company derives its key revenue from Europe and the rest from the Americas, the Middle East, Asia, Taiwan, and others.
73GF Score

Get the complete analysis for TPE:4736

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$126.00
Price
NT$111.57
GF Value